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Background
We are in an unprecedented era where the genome of an
individual can be sequenced in a day for low cost in a sin-
gle sequencing run. The availability this information is
changing and challenging the practice of medicine. At The
Medical College of Wisconsin (MCW) we have been run-
ning a whole genome sequencing (WGS) based genetics
clinic for over a year. WGS together with the processes
and tools developed for analysis and interpretation are
being used to identify disease-causing mutations in rare
pediatric disorders in children being treated at our
affiliated Children’s Hospital of Wisconsin.
Materials and methods
We have developed a fully integrated WGS process for
clinical diagnosis: from sequence generation through to
interpretation and reporting, including follow-up and
counselling tailored specifically to WGS testing. Our initial
pilot program has been extended to a Children’s Hospital
of Wisconsin clinic providing dedicated genetics staff. This
required development of a series of CAP/ CLIA compliant
protocols and pipelines for dealing with samples and
returning reports, and has spurred ongoing development
of tools including a platform for electronic health record
(EHR) data extraction. Clinically validated WGS analysis
tools were also developed to support determination of
whether the variant is: (1) a likely error, (2) known to be
causally linked with human disease, (3) of a type likely to
lead to altered function thereby giving rise to a phenotypic
change, and/or (4) within a gene with a function asso-
ciated or relevant to the patient phenotype (including
identification of causative disease genes). They support
consideration of variant and functional information simul-
taneously, as required for interpretation and reporting.
Development of this clinic also required formation of insti-
tutional review bodies, definition of a structure for coun-
selling, and development of criteria for appropriate
reporting and return of WGS-based findings.
Results
Of 22 cases approved for clinical WGS in the MCW pilot
program, 15 have been analyzed and/or reported. Our pro-
tocols and procedures have been requested and shared
with other sites moving into this area. Our tools have been
clinically validated and are in use, and continue to be
developed to add more sophisticated algorithms to sup-
port interpretation. Use of these tools has rendered diag-
noses in some but not all cases and in some cases; these
diagnoses have led to alteration in treatment in some but
not all cases [1,2]. In addition these tools are being applied
to uncovering causative mutations for dozens of additional
patients as part of various research project collaborations.
Conclusions
WGS and subsequent analysis can be used to identify cau-
sative mutations and result in diagnosis in patients with
rare disorders today. Reaching this stage requires expert
use of sophisticated bioinformatics tools for interpretation.
The diagnosis can be used to alter treatment in some
cases. We will: (1) provide examples where WGS analysis
has rendered a molecular diagnosis in individual patients
or families in the setting of novel disease, (2) highlight
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challenges faced, and (3) focus on the nature of the tools
developed and how they are used in a clinical setting.
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